Noramco Acquires Cambrex Drug Product Business Unit (Halo Pharmaceuticals)

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Cambrex Acquires Snapdragon Chemistry

January 18, 2023

Pharmaceuticals

Cambrex has acquired Snapdragon Chemistry, a Waltham, Massachusetts-based specialist in API batch and continuous flow process development. The deal brings Snapdragon's ~70–75 scientists and engineers (including 31 PhDs) and continuous flow capabilities into Cambrex's global CDMO platform to expand its process development and manufacturing offerings.

Myonex Acquires Creapharm's Pharmaceutical Services Business

May 2, 2024

Pharmaceuticals

Myonex has completed the acquisition of Creapharm's pharmaceutical services business, integrating Creapharm's clinical packaging, commercial packaging and bioservices into its global clinical trial supply platform. The deal brings Creapharm's cold-chain and ultra-cold capabilities and expands Myonex's service offering and European footprint; Creapharm founder Eric Placet has reinvested and joined the Myonex board.

Hikma Pharmaceuticals Acquires Custopharm from Water Street Healthcare Partners

September 27, 2021

Pharmaceuticals

Hikma Pharmaceuticals has agreed to acquire Custopharm Inc., a US-based generic sterile injectables company, from Water Street Healthcare Partners for an initial $375 million plus up to $50 million in contingent consideration. The acquisition adds Custopharm's 13 approved products, R&D capabilities and pipeline to Hikma's injectables franchise and is expected to be accretive to Hikma's Injectables operating margin.

Rubicon Research Acquires Impopharma Canada

January 7, 2020

Pharmaceuticals

Rubicon Research Private Limited has acquired Impopharma Canada Limited and merged it with Rubicon Research Canada Limited to establish a nasal and pulmonary development Center of Excellence in Concord, Ontario. The 13,000 sq. ft. site — previously inspected by the U.S. FDA and Health Canada — expands Rubicon's global development network and formulation/analytical capabilities; Rubicon is a portfolio company of growth investor General Atlantic.